Rhelion Life Sciences Corp. (CSE:RHEL)
Canada · Delayed Price · Currency is CAD | Market Cap | 12.28M -0.7% |
| Revenue (ttm) | 3.83M -2.8% |
| Net Income | -6.94M |
| EPS | -0.02 |
| Shares Out | 614.12M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,156,942 |
| Open | 0.0200 |
| Previous Close | 0.0200 |
| Day's Range | 0.0200 - 0.0200 |
| 52-Week Range | 0.0150 - 0.0500 |
| Beta | 0.89 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 27, 2026 |
About Rhelion Life Sciences
Rhelion Life Sciences Corp. engages in the research and development of psychedelic drug in Netherlands, Canada, and the United States. Its products also include PEX010, a natural psilocybin drug candidate. It also engages in the production, growth, and sale of functional mushrooms and mushroom home grow kits to the recreational market in North America and Europe, as well as selection, distribution, and export of truffles. The company was formerly known as Red Light Holland Corp. and changed its name to Rhelion Life Sciences Corp. in August 2026... [Read more]
Financial Performance
In fiscal year 2026, Rhelion Life Sciences's revenue was 4.20 million, a decrease of -15.15% compared to the previous year's 4.94 million. Losses were -6.10 million, 51.0% more than in 2025.
Financial StatementsNews
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Agreement to Supply PEX010 to Linkoping University for PsiloSAD Trial in Social Anxiety Disorder
Filament has signed a supply and licensing agreement with Linköping University in Sweden for PEX010 in the PsiloSAD clinical trial in social anxiety disorder. Toronto, Ontario--(Newsfile Corp. - Octob...
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Supply Belgium's First Psilocybin Compassionate Use Program, to Help Open the Door to Patient Access for Treatment-Resistant Depression
Filament has signed an agreement to supply PEX010 to Epsylon ASBL for what the Company believes will be the first program in Belgium to give patients access to psilocybin outside a clinical trial. Fil...
Rhelion Life Sciences Reappoints Dr. Robin Carhart-Harris as Scientific Advisor
Dr. Robin Carhart-Harris has signed a new agreement to serve as Scientific Advisor to Rhelion Life Sciences and its wholly owned subsidiary Filament Health. Toronto, Ontario--(Newsfile Corp. - October...
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Licence Agreement with the University of California, San Francisco for a Phase 2 Trial of Psilocybin in Methamphetamine Use Disorder Among People with HIV
Filament will supply PEX010 to a University of California, San Francisco trial testing whether a single dose of psilocybin can be used to help people living with HIV reduce methamphetamine use, a cond...
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Ships PEX010 to the University of Calgary for Phase 2 Trial of Psilocybin-Assisted Therapy for PTSD in Survivors of Intimate Partner Violence
Filament has shipped PEX010 to the University of Calgary for PsiPTSD, a Phase 2 trial of psilocybin-assisted therapy for post-traumatic stress disorder in survivors of intimate partner violence. Toron...
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Expands Supply Agreement with the University of Chieti-Pescara for PEX010 in the TEMPO Clinical Trial of Psilocybin for Treatment-Resistant Depression in Italy
Following authorization of the TEMPO trial under the European Union Clinical Trials Regulation, Filament has expanded its supply agreement with the University G. d'Annunzio of Chieti-Pescara to suppor...
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Issued New Canadian Patent, Extending the Broadest Natural Psilocybin Patent Estate
A new Canadian patent, "Psychoactive Alkaloid Extraction and Composition with Controlled Dephosphorylation," has been issued by the Canadian Intellectual Property Office, adding to the intellectual pr...
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Delivers PEX010 to Bruyere Health Research Institute's Phase 3 Trial of Microdose Psilocybin in Palliative Care
Filament has shipped PEX010 to Bruyère Health Research Institute for its Phase 3 placebo-controlled trial, which follows a published Phase I/II study that found microdose psilocybin safe, feasible and...
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the Centre for Human Drug Research for PEX010 in a Study of Low and Medium Dose Psilocybin
Filament will supply PEX010 1 mg and 5 mg capsules, with matching placebo, for a study of low and medium dose psilocybin sponsored by the Centre for Human Drug Research in Leiden, the Netherlands. Tor...
Rhelion Life Sciences Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the University of Southern California for PEX010 in a Trial for Psilocybin-Assisted Mindfulness Therapy
Toronto, Ontario--(Newsfile Corp. - September 15, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innov...
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Deliver Oral Comments at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs
Sarit Hashkes, President of Filament Health Corp., will provide oral remarks at the United States Food and Drug Administration public hearing "Considerations for Potential Future Therapeutic Use of Ps...
Rhelion Life Sciences Announces Filament Health is Planning a Stability Program for IBEX011, Its Naturally Derived Ibogaine Drug Candidate
Filament Health has begun planning a stability program for IBEX011, its naturally derived botanical ibogaine drug candidate, in response to growing demand for GMP quality, standardized ibogaine for cl...
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes Shipment of PEX010 to Australia for University of Melbourne Trial of Psilocybin-Assisted Physiotherapy in Functional Neurological Disorder
Filament Health's patented, naturally derived psilocybin drug candidate PEX010 has been shipped to Austin Health in Melbourne for PSI-PHY, an investigator initiated pilot trial of psilocybin-assisted ...
Rhelion Life Sciences Confirms Further Delivery of Filament Health's PEX010 to Germany's First Psilocybin Compassionate Use Program
Filament Health has completed a further international delivery of its patented, naturally derived psilocybin drug candidate PEX010 to Germany, supporting the first compassionate use program for psiloc...
Rhelion Life Sciences Reports First Quarter 2027 Results
Toronto, Ontario--(Newsfile Corp. - August 31, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovati...
Rhelion Life Sciences MD&A: Q1 2027
Rhelion Life Sciences filed a regulatory document on August 31, 2026 disclosing important business information.
Rhelion Life Sciences Earnings release: Q1 2027
Rhelion Life Sciences released its Q1 2027 earnings on August 31, 2026, summarizing the period's financial results.
Rhelion Life Sciences Report: Q1 2027
Rhelion Life Sciences published a report on August 31, 2026 containing material business information for investors and shareholders.
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Issued New United States Patent, Extending the Broadest Natural Psilocybin Patent Estate
A new United States patent, "Dephosphorylation-Controlled Extraction of Phosphorylatable Psychoactive Alkaloids," issued this month, adding to the intellectual property estate behind PEX010, the stand...
Rhelion Life Sciences Wholly Owned Subsidiary Filament Health Completes Shipment of PEX010 for University of Washington Phase 2a Trial in Cancer-Related Anxiety and Depression
Filament Health's patented, naturally derived psilocybin drug candidate PEX010 will be supplied to an investigator initiated Phase 2a study evaluating a group retreat model of psilocybin therapy in pe...
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Letter of Intent with Darmiyan, Inc. to Explore Use of FDA De Novo Authorized BrainSee(R) AI Platform in Early Alzheimer's Disease Trial Design
Collaboration looks to explore the use of Darmiyan's FDA De Novo authorized BrainSee® imaging platform, authorized for predicting risk of progression to Alzheimer's disease in patients with amnestic m...
Rhelion Life Sciences Announces Appointment of Samiuddin Khaja as CFO
Toronto, Ontario--(Newsfile Corp. - August 19, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovatio...
Rhelion Life Sciences Signs Agreement with University Health Network for Randomized Clinical Trial of Psilocybin in Parkinson's Disease Depression
Filament Health's patented, naturally derived psilocybin drug candidate PEX010 will be supplied to PSI-PARK, an investigator initiated randomized clinical trial evaluating psilocybin for the treatment...
Rhelion Life Sciences Corp. Commences Trading Under New Name and Ticker Symbol RHEL on the CSE
Toronto, Ontario--(Newsfile Corp. - August 4, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (OTCQB: TRUFF) (FSE: 4YX) ("Rhelion" or the "Company") is pleased to announce that it has completed its co...
Red Light Holland Reports Fiscal 2026 Audited Year-End Results and Provides Update on Rhelion Life Sciences
Toronto, Ontario--(Newsfile Corp. - July 29, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based organization advancing innov...